Cerebral to pay nearly $3.7M over controlled substance prescribing practices

Drug­mak­ers have cit­ed a range of con­sti­tu­tion­al chal­lenges in their broad fight to block the Medicare ne­go­ti­a­tion pro­vi­sions of the In­fla­tion Re­duc­tion Act, some of

Fu­ji­film Diosynth Biotech­nolo­gies will re­ceive “ag­gres­sive” in­vest­ment over the next three years from its par­ent com­pa­ny to lift rev­enues, as the CD­MO arm em­pha­sizes its